The benefits and harms of sparsentan

Sparsentan (Sparsentan), as a new drug for the treatment of primary IgA nephropathy (IgAN), has attracted much attention from the medical community in recent years. Its emergence has brought new treatment options and hope to IgAN patients. However, any drug has its two sides, and sparsentan is no exception. Below, we will introduce its efficacy and harm in detail.

1. Efficacy of Sparsentan

Sparsentan is an oral single-molecule dual-effect endothelin-angiotensin receptor antagonist (DEARA). Its main effect is to reduce proteinuria levels in patients with IgAN. It blocks two pathways related to the progression of IgA nephropathy by selectively targeting endothelin A (ETA) receptors and angiotensin II subtype 1 (AT1) receptors, thereby protecting glomerular podocytes and preventing glomerulosclerosis and mesangial cell proliferation. In clinical trials, patients treated with sparsentan reduced proteinuria by an average of 49.8% after 36 weeks of treatment. This significant therapeutic effect brings hope to IgAN patients.

2. Dangers of Sparsentan

Sparsentan also has certain hazards. First, it can cause liver toxicity. Elevations in ALT or AST of at least 3 times the upper limit of normal (ULN) were observed in patients receiving spasentan, including cases confirmed by rechallenge. Therefore, patients should have liver function tests before taking sparsentan and have liver function monitored regularly during treatment.

Secondly, sparsentan may also cause other adverse reactions, such as dizziness, anemia, high blood potassium, kidney problems, or fluid retention. Once these reactions occur, patients should stop treatment and seek medical attention immediately.

In addition, sparsentan is a prescription drug and should be used by patients under the guidance of a doctor. Do not adjust the dosage or stop taking the drug on your own. Use of spasentan during pregnancy may cause serious birth defects, so patients of childbearing potential should not become pregnant when starting spasentan, or avoid pregnancy during treatment with spasentan or for 1 month after stopping treatment.

In short, as a new drug for the treatment of primary IgA nephropathy, sparsentan has remarkable efficacy, but the harm cannot be ignored. Patients should fully understand its efficacy and hazards before use, and use it rationally under the guidance of a doctor. At present, Sparsentan is not yet available in China and cannot be purchased directly. If you need to purchase, you can consider consulting a professional overseas medical service organization.